课题基金 / 基金详情

Advanced Development of Inhibitors of human Lactate Dehydrogenase A (LDHA) as Anticancer Agents (Chemical Biology Consortium/NCI Experimental Therapeutics Collaboration)

Advanced Development of Inhibitors of human Lactate Dehydrogenase A (LDHA) as Anticancer Agents (Chemical Biology Consortium/NCI Experimental Therapeutics Collaboration)
人类乳酸脱氢酶 A (LDHA) 抑制剂作为抗癌药物的先进开发(化学生物学联盟/NCI 实验治疗合作组织)
批准号:
9551898
负责人:
Matthew Hall
金额:
$13.57万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

Matthew Hall的其他基金

相似基金

相关文献

中文摘要
翻译
在此期间,作为LDHA合作团队的一部分,NCATS小组一直致力于追求药物化学,以进一步完善化合物的效力,并在一些先进的基于细胞的分析中表征铅分子。
英文摘要
During this period, the NCATS group, as part of the LDHA collaborative team, has worked to pursue medicinal chemistry to further refine compound potencies and characterize lead molecules in a number of advanced cell-based assays. As a center, the NCGC has fostered and maintained over 130 active collaborations with both NIH and extramural investigators, facilitating drug discovery efforts across the entire spectrum of human disease. These efforts have led to dozens of high-throughput screens and a number of medicinal chemistry campaigns to further improve on screening hits, providing our collaborators and the general research community with publications and a variety of promising small molecule probes and leads. In addition, the NCGC has worked to advance a number of informatic initiatives to make better use of existing drug and disease target information and provide the general public with easily accessible resources, further catalyzing the development of new therapies for human disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
qHTS to Identify Inhibitors of Mutant and Wildtype NSD2
qHTS to Identify Activators and Inhibitors of Wip1
qHTS to Identify Compounds against Merkel Cell Carcinoma (MCC)
qHTS to Identify Activators of hTERT
海外基金